StockData
Cytek Biosciences, Inc. logo

Cytek Biosciences, Inc. (CTKB) stock

CTKBNasdaqLaboratory Analytical InstrumentsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 4, 2026Score 8/308% below fair value
$5.84+0.32 (+5.80%)

Close on Nov 13, 2026Market cap $759.10MP/E –Yield –

Cytek Biosciences gross margin

Gross margin is gross profit as a percentage of revenue.

Cytek Biosciences's gross margin for the twelve months ending Sep 30, 2026 was 54.7%. For fiscal 2025 it was 51.8%, against 55.4% the year before. The highest annual figure on record is 7283.1% in fiscal 2020.

Annual gross margin

PeriodPeriod endValueChange (pts)
FY2025Dec 31, 202551.8%−3.6
FY2024Dec 31, 202455.4%−1.3
FY2023Dec 31, 202356.7%−4.9
FY2022Dec 31, 202261.6%−3567.2
FY2021Dec 31, 20213628.8%−3654.3
FY2020Dec 31, 20207283.1%–

Quarterly gross margin

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange (pts)
Q3 FY2026Sep 30, 202658.6%+5.9
Q2 FY2026Jun 30, 202658.9%+6.5
Q1 FY2026Mar 31, 202648.2%−0.5
Q4 FY2025Dec 31, 202552.9%−5.6
Q3 FY2025Sep 30, 202552.7%−3.6
Q2 FY2025Jun 30, 202552.3%−2.2
Q1 FY2025Mar 31, 202548.6%−2.7
Q4 FY2024Dec 31, 202458.5%+1.8
Q3 FY2024Sep 30, 202456.3%−0.3
Q2 FY2024Jun 30, 202454.6%−2.1
Q1 FY2024Mar 31, 202451.3%−5.4
Q4 FY2023Dec 31, 202356.8%−4.0
Q3 FY2023Sep 30, 202356.6%−9.7
Q2 FY2023Jun 30, 202356.7%−4.5
Q1 FY2023Mar 31, 202356.7%−0.8
Q4 FY2022Dec 31, 202260.8%+0.0
Q3 FY2022Sep 30, 202266.4%+4.5
Q2 FY2022Jun 30, 202261.2%−3.8
Q1 FY2022Mar 31, 202257.5%−2.1
Q4 FY2021Dec 31, 202160.8%−2.7
Q3 FY2021Sep 30, 202161.9%−0.3
Q2 FY2021Jun 30, 202164.9%+21.7
Q1 FY2021Mar 31, 202159.7%–
Q4 FY2020Dec 31, 202063.5%–
Q3 FY2020Sep 30, 202062.2%–
Q2 FY2020Jun 30, 202043.2%–

More Cytek Biosciences figures

See a number that looks wrong?